Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nanoform Finland

0.84 EUR-2.21 %2/10 17:29
3,786 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-2.21 %
-13.22 %
+7.69 %
+94.90 %
-28.33 %
-34.38 %
-52.81 %
-89.63 %
-83.37 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
72.03M EUR
Turnover
30.35K EUR
Revenue
3.55M
EBIT %
-520.56 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
As i understand it: Nanoenzalutamid doesn’t match the Cmax corridor of the originator product (fed and fasted), but the AUC is the same. In simple terms, it can be expressed as follows: With the original drug, there is a temporary, steep rise of the active ingredient in the blood...
9/23/2026, 11:45 AM
12
Personally, I’ve only briefly understood that the problem is there is no separate regulation for “improved generics/biosimilars.” Neither in the US nor in the EU. Because to be a generic, it has to be completely identical. And then again, the whole point of nanoformulation is, of...
9/23/2026, 10:46 AM
by Clark kent
8
About the EMA Nanoenzalutmid decision there was a really interesting aspect the CEO mentioned during the Q&A: Analyst question: Obviously, you’ve had different outcomes here now from going to EMA, and then the U.K. What do you think has been the reasons for the acceptance on the ...
9/23/2026, 10:01 AM
7
So is that a guideline, not official EMA regulation? It has always remained unclear to me how many additional clinical studies these improved formulations require. The Nanoform team has probably also grown wiser through the process.
9/23/2026, 12:56 PM
by Clark kent
6
the biologics segment is surely a gem, but 2-3 years behind the small molecule segment (CESS). After they agreed on a partnership with a CDMO the machines have to be built / moved there, then their staff has to be trained by Nanoform staff. And then they are capable of producing ...
9/23/2026, 8:37 AM
6
It’s marketing. They want to tell the public that they are now able to scale their technology to that point, that they are not only “better”, but also more cost-efficient than the current ASD standard. Before they claimed just to be “better”, but now also cheaper
9/22/2026, 9:50 AM
6
The best and still the cheapest, quite a bold claim. The claims aren’t completely pulled out of thin air, though they do need independent confirmation. The market is huge, practically all the world’s medicines! In addition, there is Biopharma (Biolinja), which might turn out to be...
9/22/2026, 1:33 PM
by Korsma
5
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
11/11
2026

Interim report Q3'26

25/2
2027

Annual report '26

Press release2026-09-22 07:00

Nanoform’s CESS® technology - a Cost Leader vs Spray-dried Amorphous Solid Dispersions (ASDs)

Nanoform Finland
Regulatory press release2026-08-20 07:10

Nanoform Q2 2026 - Positive feedback from scientific advice meeting in the UK, significantly improved cash flow and discussions with CDMOs on sterile GMP for our Biologics technology initiated

Nanoform Finland
Press release2026-08-06 10:00

Invitation to Nanoform’s Q2 2026 Report Presentation

Nanoform Finland

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-05 11:00

Inside information: Positive Feedback from UK MHRA Scientific Advice Meeting regarding Nanoenzalutamide

Nanoform Finland
Regulatory press release2026-06-10 12:30

Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma

Nanoform Finland
Regulatory press release2026-06-10 12:30

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado

Nanoform Finland
Regulatory press release2026-06-10 07:30

Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2026 on remuneration of the Board of Directors

Nanoform Finland
Regulatory press release2026-05-29 18:10

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key individuals

Nanoform Finland
Regulatory press release2026-05-19 07:10

Nanoform Q1 2026 report - Record first quarter revenue, income and gross margin, first exclusivity deal signed around our Biologics technology

Nanoform Finland
Regulatory press release2026-05-12 07:00

Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery

Nanoform Finland
Press release2026-05-05 10:00

Invitation to Nanoform’s Q1 2026 Report Presentation

Nanoform Finland
Regulatory press release2026-04-21 11:20

Resolutions of Nanoform Finland Plc's Annual General Meeting on April 21, 2026

Nanoform Finland
Regulatory press release2026-04-21 11:20

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Nanoform Finland
Regulatory press release2026-04-02 08:30

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release2026-04-02 08:30

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Nanoform Finland
Regulatory press release2026-03-30 20:10

Inside information: Feedback from European Scientific Advice Meeting with Reference Member State Will Delay Submission of European Marketing Authorization Application Planned Initially for May 2026

Nanoform Finland
Regulatory press release2026-03-19 19:00

Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Nanoform Finland
Regulatory press release2026-03-02 15:00

Nanoform Finland Plc – Manager’s Transactions – David Rowe

Nanoform Finland
Regulatory press release2026-03-02 15:00

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Regulatory press release2026-03-02 15:00

Nanoform Finland Plc – Manager’s Transactions – Christian Jones

Nanoform Finland